APOGEE THERAPEUTICS, INC. COMMON STOCK
NASDAQ: APGE (Apogee Therapeutics, Inc.)
Kemas kini terakhir: 6 jam lalu83.03
1.22 (1.49%)
| Penutupan Terdahulu | 81.81 |
| Buka | 82.76 |
| Jumlah Dagangan | 686,018 |
| Purata Dagangan (3B) | 897,343 |
| Modal Pasaran | 6,255,471,616 |
| Harga / Buku (P/B) | 6.96 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 11 May 2026 |
| EPS Cair (TTM) | -3.61 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 1.75% |
| Nisbah Semasa (MRQ) | 15.82 |
| Aliran Tunai Operasi (OCF TTM) | -188.02 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -120.81 M |
| Pulangan Atas Aset (ROA TTM) | -19.65% |
| Pulangan Atas Ekuiti (ROE TTM) | -27.85% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Apogee Therapeutics, Inc. | Menurun | Bercampur |
AISkor Stockmoo
| Konsensus Penganalisis | -0.5 |
| Aktiviti Orang Dalam | -3.0 |
| Volatiliti Harga | -0.5 |
| Purata Bergerak Teknikal | 1.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.70 |
|
Apogee Therapeutics Inc is a biotechnology company seeking to develop differentiated biologics for the treatment of atopic dermatitis (AD), chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology (I&I) indications with high unmet need. Its antibody programs are designed to overcome the limitations of existing therapies by targeting well-established mechanisms of action and incorporating antibody engineering to optimize half-life and other properties. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 7.62% |
| % Dimiliki oleh Institusi | 137.71% |
Pemilikan
| Nama | Tarikh | Syer Dipegang |
|---|---|---|
| Fairmount Funds Management Llc | 31 Dec 2025 | 2,048,647 |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 95.00 (Wedbush, 14.42%) | Beli |
| Median | 88.50 (6.59%) | |
| Rendah | 82.00 (RBC Capital, -1.24%) | Pegang |
| Purata | 88.50 (6.59%) | |
| Jumlah | 1 Beli, 1 Pegang | |
| Harga Purata @ Panggilan | 68.50 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| RBC Capital | 03 Mar 2026 | 82.00 (-1.24%) | Pegang | 68.50 |
| Wedbush | 03 Mar 2026 | 95.00 (14.42%) | Beli | 68.50 |
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| HENDERSON JANE | - | 80.75 | -2,000 | -161,500 |
| Jumlah Keseluruhan Kuantiti Bersih | -2,000 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -161,500 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 80.75 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| HENDERSON JANE | Pegawai | 01 May 2026 | Jual automatik (-) | 2,000 | 80.75 | 161,500 |
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |